A Guide to Coronary Artery Disease & Cardiac Interventions for Healthcare Professionals

A Guide to Coronary Artery Disease & Cardiac Interventions for Healthcare Professionals

**Disclaimer:** This article is for informational purposes only and should not be considered medical advice. Healthcare professionals should always refer to official guidelines and clinical judgment for patient care.

Introduction

Coronary Artery Disease (CAD) stands as a formidable global health challenge, representing a leading cause of morbidity and mortality worldwide. Characterized by the insidious buildup of atherosclerotic plaque within the coronary arteries, CAD impairs blood flow to the myocardium, leading to a critical reduction in oxygen supply. This condition encompasses a spectrum of clinical presentations, from stable angina to acute coronary syndromes (ACS), including unstable angina and myocardial infarction [1]. The profound impact of CAD on public health and healthcare systems underscores the critical need for comprehensive understanding, early diagnosis, and effective management strategies among healthcare professionals.

Globally, CAD accounts for a significant proportion of deaths and disability-adjusted life years (DALYs), with a disproportionate burden observed in low- and middle-income countries. In 2015, CAD was responsible for 8.9 million deaths and 164.0 million DALYs globally, highlighting its pervasive influence on global health [1]. In the United States, CAD remains the primary cause of death, imposing an annual economic burden exceeding $200 billion on the healthcare system [13]. The increasing prevalence of CAD, driven by factors such as aging populations and the adoption of Westernized lifestyles, necessitates a robust and evolving approach to patient care. This article aims to provide healthcare professionals with a comprehensive guide to CAD, delving into its etiology, pathophysiology, diagnostic modalities, and contemporary management strategies, with a particular focus on cardiac interventions.

Etiology and Risk Factors

CAD is a multifactorial disease, resulting from a complex interplay of non-modifiable and modifiable risk factors. A thorough understanding of these factors is paramount for effective risk assessment, prevention, and patient education.

Non-Modifiable Risk Factors

Non-modifiable risk factors are inherent to an individual and cannot be altered. These include:

• **Age:** The incidence of CAD significantly increases with age, with older individuals being at a higher risk [15].
• **Gender:** Men are generally more predisposed to CAD than women, although the risk for women increases significantly post-menopause [107].
• **Family History:** A strong family history of premature CAD in first-degree relatives is a significant independent risk factor [4].
• **Genetics:** Genetic predispositions play a role in an individual\'s susceptibility to CAD, influencing lipid metabolism, inflammatory responses, and vascular health [4].

Modifiable Risk Factors

Modifiable risk factors are those that can be influenced through lifestyle changes and medical interventions. Addressing these factors is central to CAD prevention and management:

• **Hypertension:** Chronic elevated blood pressure exerts shear stress on arterial walls, promoting endothelial dysfunction and atherosclerotic plaque formation [4].
• **Smoking:** Tobacco use is a leading cause of cardiovascular disease, significantly increasing the risk of CAD by damaging endothelial cells, promoting inflammation, and altering lipid profiles [5].
• **Obesity:** Particularly central obesity, is strongly linked to increased cardiovascular disease risk. Adipose tissue, especially visceral fat, is metabolically active, releasing pro-inflammatory cytokines and contributing to insulin resistance and dyslipidemia [9] [10] [11].
• **Dyslipidemia:** Abnormal lipid levels, characterized by elevated low-density lipoprotein (LDL) cholesterol and triglycerides, and low high-density lipoprotein (HDL) cholesterol, are critical drivers of atherosclerosis [107].
• **Diabetes Mellitus:** Chronic hyperglycemia contributes to endothelial damage, oxidative stress, and accelerated atherosclerosis [4].
• **Psychosocial Variables:** Stress, depression, and anxiety have been recognized as independent risk factors for CAD, influencing lifestyle choices and physiological responses [4].

Role of Inflammation

Inflammation plays a pivotal role in the initiation and progression of atherosclerosis. Markers such as high-sensitivity C-reactive protein (hs-CRP) are considered indicators of systemic inflammation and have been associated with an increased risk of CAD, although their routine clinical utility remains a subject of ongoing debate [8].

Epidemiology

The global epidemiology of CAD reveals dynamic trends influenced by socioeconomic development, lifestyle changes, and advancements in healthcare. While developed nations have observed a decline in CAD incidence and mortality rates in recent decades, primarily due to improved acute treatments and preventive strategies, the overall burden of coronary events is not expected to decrease due to factors such as immigration and aging populations [12]. Conversely, developing countries are experiencing a sharp rise in CAD cases, attributed to the adoption of Western dietary habits and increasingly sedentary lifestyles [12].

In 2020, cardiovascular diseases (CVD), of which CAD is a major component, accounted for an estimated 19.05 million deaths worldwide, marking an 18.71% increase since 2010. The age-standardized death rate per 100,000 people was 239.80, reflecting a 12.19% decrease over the same period. The overall crude prevalence of CVD reached 607.64 million cases in 2020, representing a 29.01% increase compared to 2010 [14]. These statistics underscore the persistent and evolving challenge posed by CAD globally.

Impact of Polyvascular Disease

The presence of polyvascular disease, involving cerebral vascular disease (CeVD) and peripheral vascular disease (PVD), significantly amplifies the risk, morbidity, and mortality associated with CAD. Studies have demonstrated that patients with polyvascular disease experience higher in-hospital and one-year mortality rates following acute coronary syndromes and often exhibit more severe CAD [16] [17] [18]. This highlights the importance of a holistic assessment of vascular health in patients with suspected or confirmed CAD.

Pathophysiology

The fundamental pathological process underlying CAD is atherosclerosis, a chronic inflammatory disease characterized by the formation of plaques within the arterial walls. This process is complex and involves several key stages:

Atherosclerotic Plaque Formation

1. **Initiation:** The process begins with endothelial dysfunction, often triggered by risk factors such as hypertension, dyslipidemia, and smoking. This leads to increased permeability of the endothelium, allowing low-density lipoprotein (LDL) particles to accumulate in the subendothelial space. 2. **Fatty Streak Formation:** Monocytes adhere to the dysfunctional endothelium, migrate into the intima, and differentiate into macrophages. These macrophages engulf oxidized LDL particles, transforming into foam cells. The accumulation of foam cells forms visible fatty streaks [129]. 3. **Plaque Progression:** Smooth muscle cells (SMCs) migrate from the media to the intima, proliferate, and produce extracellular matrix components, forming a fibrous cap over the lipid core. As the plaque grows, it narrows the arterial lumen, impeding blood flow [129].

Plaque Stability and Calcification

Plaque stability is a critical determinant of clinical outcomes. Stable plaques typically have a thick fibrous cap and a small lipid core, while unstable (vulnerable) plaques are characterized by a thin fibrous cap, a large lipid core, and significant inflammation. Calcification within the plaque also plays a complex role:

• **Microcalcifications:** Small calcified deposits can increase mechanical stress within the fibrous cap, making it more prone to rupture [151].
• **Macrocalcifications:** Larger, more organized calcifications are often associated with stable plaques and can provide structural stability. However, extensive calcification can also lead to nodular calcification, increasing the risk of plaque rupture and thrombosis [151].

Classification of Coronary Artery Disease

CAD is broadly classified into several forms, each with distinct clinical implications [133]:

• **Stable Ischemic Heart Disease (SIHD):** Characterized by stable angina, where symptoms are predictable and occur with exertion, relieved by rest or nitroglycerin.
• **Acute Coronary Syndromes (ACS):** A spectrum of conditions requiring urgent medical attention, including:
• **ST-Elevation Myocardial Infarction (STEMI):** Complete occlusion of a coronary artery, leading to myocardial necrosis and ST-segment elevation on ECG.
• **Non-ST-Elevation Myocardial Infarction (NSTEMI):** Partial occlusion or transient complete occlusion, resulting in myocardial necrosis without persistent ST-segment elevation.
• **Unstable Angina:** Chest pain at rest or with minimal exertion, or a worsening pattern of stable angina, without evidence of myocardial necrosis.

Clinical Presentation and Diagnosis

The clinical presentation of CAD can vary widely, from asymptomatic disease to life-threatening acute events. Healthcare professionals must be adept at recognizing both typical and atypical symptoms to ensure timely diagnosis and intervention.

Angina Pectoris

Angina pectoris, the most common symptom of CAD, is typically described as a discomfort in the chest, often retrosternal, that may radiate to the left arm, neck, jaw, teeth, or ear. It is usually triggered by physical exertion or emotional stress and relieved by rest or nitrates [156].

• **Stable Angina:** Predictable chest pain that occurs with a consistent level of exertion and is relieved by rest or nitroglycerin.
• **Unstable Angina:** Chest pain that occurs at rest, is new in onset, or is significantly more severe or frequent than previous angina. This indicates a higher risk of myocardial infarction [160].

Atypical Symptoms

It is crucial to recognize that CAD can present with atypical symptoms, particularly in women, older individuals, and patients with diabetes. These may include dyspnea, fatigue, nausea, dizziness, epigastric pain, or back pain [158]. Atypical presentations can lead to diagnostic delays and poorer outcomes [162].

Physical Examination

A thorough physical examination is essential, though findings may be normal in stable CAD. Key aspects include inspection for acute distress, jugular venous distention, and peripheral edema; palpation for thrills or heaves; and auscultation of the heart and lungs for murmurs, gallops, or rales [164].

Challenges in Diagnosis

Misdiagnosis of CAD, especially in cases with atypical symptoms or subtle ECG changes, can have serious consequences. A significant proportion of myocardial infarctions may be asymptomatic or present with non-classic symptoms, leading to delayed or missed diagnoses [162] [166].

Diagnostic Modalities

A variety of diagnostic tools are available to evaluate CAD, ranging from non-invasive tests to invasive procedures. The choice of modality depends on the patient\'s clinical presentation, risk factors, and the urgency of the situation.

Electrocardiogram (ECG)

ECG is a fundamental and readily available tool for evaluating CAD. It measures the electrical activity of the heart and can provide crucial information about cardiac rate, rhythm, and axis. In acute settings, ECG can detect ST-segment and T-wave changes indicative of ACS, as well as arrhythmias. In chronic CAD, it may reveal abnormalities such as axis deviation, bundle branch blocks, or ventricular hypertrophy [175] [177]. Prehospital ECGs by emergency medical services (EMS) personnel are increasingly utilized to facilitate early diagnosis and intervention, particularly for STEMI [181].

Echocardiography

Echocardiography, or cardiac ultrasound, is a valuable non-invasive imaging technique. It assesses wall motion abnormalities, valvular function, chamber sizes, and pericardial effusions. In acute settings, it can help diagnose acute pulmonary pathologies. Stress echocardiography, often performed with exercise or pharmacological agents (e.g., dobutamine), evaluates myocardial ischemia by detecting wall motion abnormalities under stress. Advanced protocols, such as the European Society of Cardiology\'s ABCDE protocol, integrate multiple biomarkers for comprehensive risk stratification in chronic coronary syndromes [187] [193].

Stress Testing

Stress testing is a non-invasive method to identify myocardial ischemia. During the test, the heart is subjected to controlled stress (exercise or pharmacological) while monitoring ECG changes and symptoms. The test is considered positive for CAD if the patient develops anginal symptoms or significant ST-segment changes. Various methods, including exercise, dobutamine, and vasodilators (dipyridamole or adenosine), are used to induce stress [197] [199].

Chest Radiography

Chest radiography is an essential component of the initial evaluation of cardiac disease. While not specific for CAD, it can provide valuable information about heart size, pulmonary congestion, and other thoracic pathologies that may mimic or coexist with CAD [203].

Serum Markers

Blood tests play a role in diagnosing and monitoring CAD. In acute settings, cardiac enzymes (e.g., troponin) are crucial for detecting myocardial necrosis. B-type natriuretic peptides (BNP) provide information about volume overload of cardiogenic origin, although their interpretation requires consideration of factors like kidney disease and obesity [207].

Cardiac Catheterization

Cardiac catheterization with coronary angiography is considered the gold standard for evaluating ischemic coronary heart disease. This invasive procedure directly visualizes the coronary arteries, allowing for assessment of the type, number, and severity of stenoses. It is indicated in patients with ACS and those with intermediate pretest probability for CAD in non-ACS settings. While highly accurate, it carries risks such as allergic reactions to contrast and kidney injury [213] [215].

Coronary Calcium Score and Computed Tomography Angiography (CCTA)

Coronary Artery Calcium (CAC) scoring and CCTA are non-invasive imaging techniques that can assess the presence and extent of coronary atherosclerosis. A CAC score of zero in symptomatic patients can effectively rule out obstructive CAD. CCTA provides detailed anatomical information about coronary stenoses and plaque characteristics, aiding in risk stratification and guiding further management [221] [223].

Treatment and Management

The management of CAD is tailored to the specific clinical presentation, whether it is stable ischemic heart disease (SIHD) or acute coronary syndrome (ACS). The overarching goals are to alleviate symptoms, prevent adverse cardiovascular events, and improve quality of life.

Stable Ischemic Heart Disease (SIHD)

Management of SIHD involves a combination of nonpharmacologic and pharmacologic interventions:

Nonpharmacologic Interventions

Lifestyle modifications are foundational to SIHD management and include:

• **Smoking Cessation:** The most impactful intervention for reducing cardiovascular risk.
• **Regular Exercise:** Improves endothelial function, reduces blood pressure, and enhances collateral circulation.
• **Weight Loss:** Particularly for individuals with obesity, to reduce cardiovascular burden.
• **Healthy Diet:** Emphasizing fruits, vegetables, whole grains, lean proteins, and limiting saturated fats, trans fats, and sodium.
• **Diabetes and Hypertension Control:** Strict management of these comorbidities is essential [232].

Pharmacologic Interventions

Guideline-directed medical therapy (GDMT) is crucial for SIHD and typically includes:

• **Antiplatelet Agents:** Low-dose aspirin is recommended for most patients to prevent thrombotic events. P2Y12 inhibitors may be added in certain circumstances [234].
• **Beta-Blockers:** Reduce myocardial oxygen demand by decreasing heart rate and contractility, thereby alleviating angina. They are particularly beneficial post-myocardial infarction [234].
• **Nitroglycerin:** Used for acute symptom relief and as a prophylactic measure before activities that may trigger angina [234].
• **Statins:** High-intensity statins are essential for lipid lowering and plaque stabilization, significantly reducing the risk of cardiovascular events [234].
• **Calcium Channel Blockers:** Can be used as an alternative or adjunct to beta-blockers for symptom control, especially in patients with contraindications to beta-blockers or persistent angina [234].
• **Ranolazine:** An antianginal agent that can be added for refractory symptoms despite optimal GDMT [234].

Revascularization

For patients with persistent symptoms despite optimal medical therapy, or those with high-risk anatomical features, revascularization procedures may be considered:

• **Percutaneous Coronary Intervention (PCI):** A minimally invasive procedure involving angioplasty and stent placement to open narrowed or blocked coronary arteries [79].
• **Coronary Artery Bypass Grafting (CABG):** A surgical procedure that bypasses blocked coronary arteries using grafts from other parts of the body, typically indicated for multi-vessel disease or complex lesions [79].

Acute Coronary Syndrome (ACS)

ACS requires immediate and aggressive management to limit myocardial damage and prevent complications.

Initial Management

• **Prompt ECG:** Essential for differentiating STEMI from NSTEMI/unstable angina [238].
• **Antiplatelet Therapy:** Aspirin is administered immediately, often followed by a P2Y12 inhibitor (e.g., clopidogrel, ticagrelor, prasugrel) [242].
• **Anticoagulation:** Heparin or enoxaparin is typically initiated [244].
• **Nitrates:** For pain relief, provided there are no contraindications (e.g., hypotension, recent phosphodiesterase inhibitor use) [242].
• **Beta-Blockers and Statins:** Initiated early to reduce myocardial oxygen demand and stabilize plaque [242].

STEMI Management

STEMI is a medical emergency requiring urgent reperfusion to restore blood flow to the ischemic myocardium:

• **Primary PCI:** The preferred reperfusion strategy, ideally performed within 90 minutes of first medical contact at a PCI-capable facility [240].
• **Fibrinolytic Therapy:** If primary PCI is not available within 120 minutes, fibrinolytic therapy is an alternative, followed by transfer to a PCI-capable facility [240].

NSTEMI/Unstable Angina Management

Patients with NSTEMI or unstable angina are risk-stratified to guide management. High-risk patients typically undergo early invasive therapy (coronary angiography with possible PCI/CABG) within 24 hours [244].

Long-Term Management

Long-term management of all CAD patients involves continued medication adherence, aggressive risk factor modification, and regular follow-up with cardiologists and primary care physicians. Dual antiplatelet therapy (DAPT) duration is a critical consideration, balancing the risk of stent thrombosis with bleeding risk, often guided by clinical trials and patient characteristics [248] [250] [252].

Complications of CAD

CAD can lead to a range of serious complications, significantly impacting patient prognosis and quality of life. Understanding these complications is vital for comprehensive patient care.

Arrhythmias

Myocardial ischemia and infarction can predispose patients to various arrhythmias, including ventricular arrhythmias, atrial fibrillation, and atrioventricular blocks. The management of these arrhythmias depends on their type, timing, and the patient\'s hemodynamic stability [277] [278].

Congestive Heart Failure (CHF)

Pathological left ventricular remodeling following myocardial infarction can lead to the development of chronic heart failure. Monitoring left ventricular ejection fraction (LVEF) and heart rate variability are crucial for assessing CHF progression and prognosis [284] [286].

Mitral Regurgitation

Ischemic mitral regurgitation can occur due to left ventricular remodeling and papillary muscle dysfunction, further exacerbating heart failure symptoms and worsening prognosis [289] [290].

Mechanical Complications

Although less common in the era of reperfusion therapy, mechanical complications such as papillary muscle rupture (PMR), ventricular septal defects (VSDs), and ventricular free wall rupture (FWR) are catastrophic events associated with high mortality [296] [298].

Pericarditis

Postmyocardial infarction pericarditis (PMIP) is an inflammatory condition of the pericardium that can occur after an MI. While it can worsen short-term outcomes, it typically does not affect long-term prognosis [301] [302].

Aneurysm Formation

Left ventricular aneurysms can form after a large myocardial infarction, particularly anterior MIs. These can lead to complications such as ventricular arrhythmias, thrombus formation, and pump failure [307] [310].

Mural Thrombi

Ventricular mural thrombi can form in the left ventricle, especially after anterior MIs, increasing the risk of systemic embolization and stroke. Contrast echocardiography is an effective tool for their detection [312] [316].

Toxicity and Adverse Effect Management

Both medical and interventional therapies for CAD carry potential risks and side effects that healthcare professionals must manage effectively.

Medication Side Effects

• **Aspirin:** Can cause bleeding, gastrointestinal upset, and allergic reactions [262].
• **Statins:** Common side effects include myalgias, diarrhea, and arthralgia. More serious but rare side effects include rhabdomyolysis and liver dysfunction [262].
• **Beta-Blockers:** Can lead to bradycardia, hypotension, fatigue, and bronchospasm in susceptible individuals [264].
• **ACE Inhibitors:** May cause hypotension, dizziness, cough, and angioedema [264].

Intervention Complications

• **PCI:** Potential complications include coronary artery perforation, stent thrombosis (acute or late), and in-stent restenosis [264].
• **CABG:** Risks include arrhythmias, cardiac tamponade, postoperative bleeding, infection, renal impairment, and phrenic nerve injury [264].

Careful patient selection, meticulous technique, and comprehensive patient education are crucial for mitigating these adverse effects.

Prognosis

The prognosis of CAD is highly variable and depends on a multitude of factors, including the extent of coronary artery involvement, left ventricular function, presence of comorbidities (e.g., diabetes, hypertension, chronic kidney disease), and adherence to medical therapy and lifestyle modifications. Age, gender, genetics, and socioeconomic status also play a role [269]. Aggressive risk factor management and adherence to guideline-directed therapies significantly improve long-term outcomes.

Deterrence and Patient Education

Primary care providers play a pivotal role in the deterrence of CAD through proactive risk factor modification. Patient education on the importance of smoking cessation, healthy diet, regular exercise, weight management, and strict control of diabetes, hypertension, and dyslipidemia is paramount. Public awareness campaigns through various media outlets and school curricula are also essential to address CAD as a global public health concern [321].

Enhancing Healthcare Team Outcomes

Given the complex and multifaceted nature of CAD, an interprofessional team approach is essential for optimizing patient outcomes. While cardiologists are central to CAD management, collaboration with other specialists, including gastroenterologists, pulmonologists, psychiatrists, and radiologists, is often necessary to address coexisting conditions and diagnostic dilemmas. Nurses are integral to patient care, providing critical bedside information, administering medications, and educating patients and families. A coordinated team effort ensures comprehensive and holistic care for patients with CAD [333].

References

[1] Ralapanawa U, Sivakanesan R. Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review. J Epidemiol Glob Health. 2021 Jun;11(2):169-177. [PMC free article] [PubMed] [2] Dalen JE, Alpert JS, Goldberg RJ, Weinstein RS. The epidemic of the 20(th) century: coronary heart disease. Am J Med. 2014 Sep;127(9):807-12. [PubMed] [3] Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. J Am Coll Cardiol. 2019 Nov 19;74(20):2529-2532. [PubMed] [4] Bauersachs R, Zeymer U, Brière JB, Marre C, Bowrin K, Huelsebeck M. Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review. Cardiovasc Ther. 2019;2019:8295054. [PMC free article] [PubMed] [5] Jamal A, Phillips E, Gentzke AS, Homa DM, Babb SD, King BA, Neff LJ. Current Cigarette Smoking Among Adults - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):53-59. [PMC free article] [PubMed] [6] Petrazzini BO, Chaudhary K, Márquez-Luna C, Forrest IS, Rocheleau G, Cho J, Narula J, Nadkarni G, Do R. Coronary Risk Estimation Based on Clinical Data in Electronic Health Records. J Am Coll Cardiol. 2022 Mar 29;79(12):1155-1166. [PMC free article] [PubMed] [7] Nasir K, DeFilippis A. Big Data and ASCVD Risk Prediction: Building a Better Mouse Trap? J Am Coll Cardiol. 2022 Mar 29;79(12):1167-1169. [PubMed] [8] Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol. 2013 Oct 15;168(6):5126-34. [PubMed] [9] Klein S, Allison DB, Heymsfield SB, Kelley DE, Leibel RL, Nonas C, Kahn R., Association for Weight Management and Obesity Prevention. NAASO, The Obesity Society. American Society for Nutrition. American Diabetes Association. Waist circumference and cardiometabolic risk: a consensus statement from Shaping America\'s Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Am J Clin Nutr. 2007 May;85(5):1197-202. [PubMed] [10] Ross R, Neeland IJ, Yamashita S, Shai I, Seidell J, Magni P, Santos RD, Arsenault B, Cuevas A, Hu FB, Griffin BA, Zambon A, Barter P, Fruchart JC, Eckel RH, Matsuzawa Y, Després JP. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol. 2020 Mar;16(3):177-189. [PMC free article] [PubMed] [11] Sharma S, Batsis JA, Coutinho T, Somers VK, Hodge DO, Carter RE, Sochor O, Kragelund C, Kanaya AM, Zeller M, Park JS, Køber L, Torp-Pedersen C, Lopez-Jimenez F. Normal-Weight Central Obesity and Mortality Risk in Older Adults With Coronary Artery Disease. Mayo Clin Proc. 2016 Mar;91(3):343-51. [PubMed] [12] Ferreira-González I. The epidemiology of coronary heart disease. Rev Esp Cardiol (Engl Ed). 2014 Feb;67(2):139-44. [PubMed] [13] Brown JC, Gerhardt TE, Kwon E. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 23, 2023. Risk Factors for Coronary Artery Disease. [PubMed] [14] Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK, Buxton AE, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Fugar S, Generoso G, Heard DG, Hiremath S, Ho JE, Kalani R, Kazi DS, Ko D, Levine DA, Liu J, Ma J, Magnani JW, Michos ED, Mussolino ME, Navaneethan SD, Parikh NI, Poudel R, Rezk-Hanna R, Roth GA, Shah NS, St-Onge MP, Thacker EL, Virani SS, Voeks JH, Wang NY, Wong ND, Wong SS, Yaffe K, Martin SS., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023 Feb 21;147(8):e93-e621. [PubMed] [15] Puymirat É. [Epidemiology of coronary artery disease]. Rev Prat. 2015 Mar;65(3):317-20. [PubMed] [16] Al Thani H, El-Menyar A, Alhabib KF, Al-Motarreb A, Hersi A, Alfaleh H, Asaad N, Saif SA, Almahmeed W, Sulaiman K, Amin H, Alsheikh-Ali AA, Alnemer K, Suwaidi JA. Polyvascular disease in patients presenting with acute coronary syndrome: its predictors and outcomes. ScientificWorldJournal. 2012;2012:284851. [PMC free article] [PubMed] [17] Ferreira-González I, Permanyer Miralda G, Heras M, Ribera A, Marsal JR, Cascant P, Arós F, Bueno H, Sánchez PL, Cuñat J, Civeira E, Marrugat J., Investigadores del Estudio MASCARA. Prognosis and management of patients with acute coronary syndrome and polyvascular disease. Rev Esp Cardiol. 2009 Sep;62(9):1012-21. [PubMed] [18] Cotter G, Cannon CP, McCabe CH, Michowitz Y, Kaluski E, Charlesworth A, Milo O, Bentley J, Blatt A, Krakover R, Zimlichman R, Reisin L, Marmor A, Lewis B, Vered Z, Caspi A, Braunwald E., OPUS-TIMI 16 Investigators. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J. 2003 Apr;145(4):622-7. [PubMed] [19] Calais F, Eriksson Östman M, Hedberg P, Rosenblad A, Leppert J, Fröbert O. Incremental prognostic value of coronary and systemic atherosclerosis after myocardial infarction. Int J Cardiol. 2018 Jun 15;261:6-11. [PubMed] [20] Weight N, Moledina S, Zoccai GB, Zaman S, Smith T, Siller-Matula J, Dafaalla M, Rashid M, Nolan J, Mamas MA. Impact of pre-existing vascular disease on clinical outcomes. Eur Heart J Qual Care Clin Outcomes. 2022 Dec 13;9(1):64-75. [PubMed] [21] Nakahara T, Dweck MR, Narula N, Pisapia D, Narula J, Strauss HW. Coronary Artery Calcification: From Mechanism to Molecular Imaging. JACC Cardiovasc Imaging. 2017 May;10(5):582-593. [PubMed] [22] Hashmi S, Shah PW, Aherrahrou Z, Aikawa E, Aherrahrou R. Beyond the Basics: Unraveling the Complexity of Coronary Artery Calcification. Cells. 2023 Dec 12;12(24) [PMC free article] [PubMed] [23] DeVon HA, Mirzaei S, Zègre-Hemsey J. Typical and Atypical Symptoms of Acute Coronary Syndrome: Time to Retire the Terms? J Am Heart Assoc. 2020 Apr 07;9(7):e015539. [PMC free article] [PubMed] [24] Abdullatef M, Omran M, Bitar A, Alsaid B. Prevalence of classic and non-classic pain sites of coronary artery disease: a cross-sectional study. BMC Cardiovasc Disord. 2024 Aug 24;24(1):445. [PMC free article] [PubMed] [25] Fan J, Liu Y, Wang Y, Li Y, Wang H, Zhang M, Zhang S, Zhang J, Li W, Wang L, Zhao D. Prehospital electrocardiogram in patients with acute coronary syndrome: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2023 Mar 15;23(1):129. [PMC free article] [PubMed] [26] DeVon HA, Penckofer S, Larimer ME, Zerwic JJ. Gender differences in symptom presentation in patients with acute coronary syndromes. J Cardiovasc Nurs. 2007 Nov-Dec;22(6):479-86. [PubMed] [27] Nagueh SF. Echocardiography in Coronary Artery Disease. J Am Coll Cardiol. 2019 Sep 17;74(11):1479-1490. [PubMed] [28] Picano E, Pibarot P, Lancellotti P, Monin JL, Sicari R, Van de Werf F. The ABCDE of stress echocardiography: a comprehensive approach to risk stratification in patients with chronic coronary syndromes. Eur Heart J. 2019 Oct 1;40(37):3075-3085. [PubMed] [29] Gibbons RJ, Balady GJ, Bricker BJ, Chaitman BD, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Moossian B, O\'Reilly MG, Perrault PM, Pina IL, Smith EH, Stewart WJ, Winters WL Jr, Zoghbi WA. ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003 Jan 1;41(1):159-68. [PubMed] [30] Kern MJ, Samady H. Current Concepts of Integrated Coronary Physiology in the Catheterization Laboratory. J Am Coll Cardiol. 2019 Mar 12;73(9):1090-1105. [PubMed] [31] Sones FM Jr, Shirey EK. Cine coronary arteriography. Mod Concepts Cardiovasc Dis. 1962 Jul;31:735-8. [PubMed] [32] Aglen Za, Kofoed KF, Kjeldsen SE, Olsen RH, Aaberge L, Haugaa KH, Edvardsen T. Prognostic value of coronary artery calcium score and coronary computed tomography angiography in symptomatic patients with suspected coronary artery disease. Eur Heart J Cardiovasc Imaging. 2020 Feb 1;21(2):186-194. [PubMed] [33] Fihn SD, Blankenship Z, Alexander KP, Bittl JA, Fuster V, Ghandour FD, Green LA, Hlatky MR, Hochman JA, Jones DW, Jneid K, Kashyap SM, Krumholz HM, Kwong RS, Lim MJ, Linderbaum BL, Mack MJ, Mahrholdt M, Prasad A, Smith PK, Smith SC Jr, Spertus JA, Williams SV. 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014 Nov 25;64(21):2304-18. [PubMed] [34] Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller G, Kristensen SJ, Niebauer J, Richter DJ, Seferovic PG, Sibbing D, Stefanini GC, Stiegelmeier Z, Windecker S, Witkowski A, Wreczycka M. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. [PubMed] [35] Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Baumgartner MJ, Ceconi C, Dean V, Filippatos B, Hamm C, Kastrati A, Lancellotti P, Lansky AJ, Luscher TF, Rademakers P, Reimer J, Roffi M, Sousa-Uva M, Taggart DP, Vahanian A, Windecker S, Zamorano JL. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315. [PubMed] [36] Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio AC, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Katus HU, Knuuti S, Lenzen M, Prescott EW, Roffi M, Valgimigli M, Varenne S, Widimsky P, Windecker S. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177. [PubMed] [37] Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey DP, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned B, Franzosi MG, Habersberger R, Ibanez B, Kjeldsen K, Lancellotti P, Mehilli V, Merkely B, Montalescot G, Richter DJ, Roffi M, Sessa F, Valgimigli M, van der Woude H, Visseren FLJ, Wendler O, Windecker S, Zamorano JL. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-477. [PubMed] [38] Kim BK, Hong MK, Shin DH, Kim JS, Ko YG, Choi D, Jang Y, Park SJ. Effect of 6-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the RESET randomized trial. J Am Coll Cardiol. 2012 Oct 23;60(17):1620-9. [PubMed] [39] Koo BK, Kang J, Park KW, Kim HS, Kim YJ, Kim SH, Lee HY, Lee SH, Park SH, Park TH, Park Y, Rha SW, Seo HS, Seung KB, Shin ES, Song YB, Yang DH, Yoon JH, Jang Y, Kim H, Kim KB, Kim MH, Kim PJ, Kim SW, Kim YH, Lee JH, Lee SW, Lee SY, Lim DS, Oh JH, Oh SK, Park DW, Park HS, Park JS, Park SW, Park YH, Shin JH, Won H, Yu CW. Aspirin versus clopidogrel for long-term maintenance after percutaneous coronary intervention with drug-eluting stents (HOST-EXAM): a multicentre, prospective, randomised, open-label trial. Lancet. 2021 Jan 23;397(10271):313-323. [PubMed] [40] Patrono C, Collet JP, Fitzgerald GA, Halvorsen S, Rocca B, Valgimigli M, Verheugt FW. Antiplatelet Agents: A Compendium of Guidelines. J Am Coll Cardiol. 2017 Oct 17;70(16):2021-2038. [PubMed] [41] Newman CB, Preiss D, Tobert JO, Jacobson TA, Holbrooke JH, Palmer WC, Guyton JR, Kris-Etherton PM, Brown WV, Mackey RH, McNeal CJ, Brinton EA, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-e81. [PubMed] [42] Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-Converting Enzyme Inhibitors in Hypertension: Are They All the Same? J Am Coll Cardiol. 2018 Sep 18;72(12):1407-1416. [PubMed] [43] Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea R, Mintz GS, Serruys PW, Windecker S, van Geuns RJ, de Winter RJ, D\'Ascenzo F, Roffi M, Wijns W, Mehran R. A Prospective, Natural-History Study of Coronary Atherosclerosis. N Engl J Med. 2011 Nov 17;365(20):1863-71. [PubMed] [44] Fox K, Garcia MA, Steg PG, Tendera A, Ferrari R, Group ES. Long-term outcome in patients with stable coronary artery disease: results from the EUROPA study. Eur Heart J. 2007 Apr;28(7):864-71. [PubMed] [45] Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MA, Fonarow GC, Geraci SA, Horwich F, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FM, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Vardeny Z, Whelan CL, Zile MR. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(14):e147-239. [PubMed] [46] Krumholz HM, Chen YT, Vaccarino V, Setaro JF, Radford MJ, Lytle BL. Correlates of long-term mortality in patients with acute myocardial infarction. JAMA. 1197 Dec 17;278(23):2151-6. [PubMed] [47] Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Peterson ED, Poole JE, Rosenberg YD, Smith PK, Van Wagoner DR, Walsh RA. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018 Oct 2;72(14):e91-e220. [PubMed] [48] Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde L, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Tendera F, Van der Meer A, Van Veldhuisen DJ. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. [PubMed] [49] Dziuba M, Chyrchel B, Gackowski A, Pieniazek P, Kostkiewicz M, Podolec P. Prevalence and Prognostic Significance of Mitral Regurgitation in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J Clin Med. 2020 Jul 29;9(8):2409. [PMC free article] [PubMed] [50] Elbadawi A, Elgendy IY, Mahmoud K, Barakat AF, Mentias A, Mohamed AH, Mojadidi MK, Omer MA, Abuzaid A, Al-Ani M, Mando R, Elshazly MB, Wayangankar SA, Abbott JD, Jneid H, Bavry AA. Temporal Trends and Outcomes of Mechanical Complications in Patients With Acute Myocardial Infarction. JACC Cardiovasc Interv. 2019 Oct 28;12(20):2069-2079. [PubMed] [51] Imazio M, Gaita F, LeWinter M. Diagnosis and Treatment of Pericarditis. Circulation. 2015 Oct 13;132(15):1442-51. [PubMed] [52] Elbadawi A, Elgendy IY, Mahmoud K, Barakat AF, Mentias A, Mohamed AH, Mojadidi MK, Omer MA, Abuzaid A, Al-Ani M, Mando R, Elshazly MB, Wayangankar SA, Abbott JD, Jneid H, Bavry AA. Trends in the Incidence and Outcomes of Left Ventricular Aneurysm in Patients With Acute Myocardial Infarction. J Am Heart Assoc. 2020 Jan 21;9(2):e014022. [PMC free article] [PubMed] [53] Senthilkumaran S, Balamurugan N, Suresh P, Ambika S, Thirumalaikolundusubramanian P. Left ventricular mural thrombus in acute myocardial infarction: a review. J Cardiovasc Dis Res. 2012 Jul;3(3):161-7. [PMC free article] [PubMed] [54] Patrono C, Collet JP, Fitzgerald GA, Halvorsen S, Rocca B, Valgimigli M, Verheugt FW. Antiplatelet Agents: A Compendium of Guidelines. J Am Coll Cardiol. 2017 Oct 17;70(16):2021-2038. [PubMed] [55] Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal S, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 8;350(15):1495-504. [PubMed]